David Steinberg is out with a cautious note on Teva, believing much of the outlook is priced into the stock.
Mizuho’s Difei Yang approaches the biotech player as a new bull, angling for a whopping 204% in return potential for MRNS shares.
Cowen’s Eric Schmidt gives a vote of confidence to ADAP on back of yesterday’s fourth quarter financial and pipeline update.
H.C. Wainwright’s Ram Selvaraju is glad to see VRX pushing out maturities on its massive debt- but still sees a “rock” rolling down the path.
Guggenheim’s Rohit Vanjani is reassured from the sidelines on TEVA’s fremanezumab’s prospects to clear an FDA not despite supply plant’s Warning Letter.
H.C. Wainwright’s Swayampakula Ramakanth believes this failure now “casts doubt” on VBLT’s therapeutic prospects for its VB-111 asset.